Jesus Fernandez-Sojo

Dr. Jesus Fernandez-Sojo

orcid

Research Focus & Metrics

Academic Career Length

8Years (2019-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
19 August 2019 in PLOS Pathogens
Verified
Journal Article
Open access
PDF file
JGJudith Grau-Expósito
Judith Grau-Expósito
LLLaura Luque-Ballesteros
Laura Luque-Ballesteros
JNJordi Navarro
Jordi Navarro
ACAdrian Curran
Adrian Curran
JBJoaquin Burgos
Joaquin Burgos
MBMaria Jose Buzon
Maria Jose Buzon
Latency reversal agents (LRAs) have proven to induce HIV-1 transcription in vivo but are ineffective at decreasing the size of the latent reservoir in antiretroviral treated patients. The capacity of the LRAs to perturb the viral reservoir present in distinct subpopulations of cells is currently unknown. Here, using a new RNA FISH/flow ex vivo viral reactivation assay, we performed a comprehensive assessment of the viral reactivation capacity of different families of LRAs, and their combinations, in different CD4+ T cell subsets. We observed that a median of 16.28% of the whole HIV-reservoir induced HIV-1 transcripts after viral reactivation, but only 10.10% of these HIV-1 RNA+ cells produced the viral protein p24. Moreover, none of the LRAs were powerful enough to reactivate HIV-1 transcription in all CD4+ T cell subpopulations. For instance, the combination of Romidepsin and Ingenol was identified as the best combination of drugs at increasing the proportion of HIV-1 RNA+ cells, in most, but not all, CD4+ T cell subsets. Importantly, memory stem cells were identified as highly resistant to HIV-1 reactivation, and only the combination of Panobinostat and Bryostatin-1 significantly increased the number of cells transcribing HIV within this subset. Overall, our results validate the use of the RNA FISH/flow technique to assess the potency of LRAs among different CD4+ T cell subsets, manifest the intrinsic differences between cells that encompass the latent HIV reservoir, and highlight the difficulty to significantly impact the latent infection with the currently available drugs. Thus, our results have important implications for the rational design of therapies aimed at reversing HIV latency from diverse cellular reservoirs. HIV infection is an incurable disease. Despite antiretroviral therapy, a pool of cells with HIV in a latent state persists and precludes fully eradication of the viral infection. The cells that contain this latent viral reservoir are very diverse, and therefore different therapeutic strategies would be necessary to target and eliminate all infected cells. Latency Reversal Agents (LRAs) are compounds able to awake the latent virus from its dormant state with the purpose of making infected cells visible to the immune system. But the ability of the LRAs to target different cell types containing HIV is currently unknown. Here, using a novel methodology that interrogates individual cells, we found that current LRAs do not impact equally all infected cells. In fact, certain types of memory lymphocytes, recognized to harbor latent HIV for decades, are not fully impacted by most of the LRAs tested. Our study highlights the difficulty to cure HIV with the currently available LRAs. Different therapeutic approaches aimed at reversing HIV latency from diverse cellular reservoirs are needed to reduce HIV persistence.

14 June 2021 in Bone Marrow Transplantation
Verified
Journal Article
Closed access
PDF file
JFJesus Fernandez-Sojo
Jesus Fernandez-Sojo
CACarmen Azqueta
Carmen Azqueta
EVElena Valdivia
Elena Valdivia
LMLluis Martorell
Lluis Martorell
LMLaura Medina-Boronat
Laura Medina-Boronat
SGSergi Querol Giner
Sergi Querol Giner

8 July 2022 in Bone Marrow Transplantation
Verified
Journal Article
Closed access
PDF file
JFJesus Fernandez-Sojo
Jesus Fernandez-Sojo
RHRoger Horton
Roger Horton
JCJoan Cid
Joan Cid
CACarmen Azqueta
Carmen Azqueta
AGAna Garcia-Buendia
Ana Garcia-Buendia
SGSergi Querol Giner
Sergi Querol Giner

1 March 2021 in Vox Sanguinis
Verified
Journal Article
Closed access
PDF file
CMChristina Mikkelsen
Christina Mikkelsen
GMGaia Mori
Gaia Mori
SWSuzanna M. van Walraven
Suzanna M. van Walraven
JCJohanna Castrén
Johanna Castrén
SZSharon Zahra
Sharon Zahra
HUHenrik Ullum
Henrik Ullum

27 August 2022 in Cytotherapy
Verified
Journal Article
Closed access
PDF file
JFJesus Fernandez-Sojo
Jesus Fernandez-Sojo
JDJoaquim Delgadillo
Joaquim Delgadillo
JVJoaquim Vives
Joaquim Vives
LRLuciano Rodriguez
Luciano Rodriguez
AMAna Mendoza
Ana Mendoza
SQSergio Querol
Sergio Querol

26 October 2020 in Vox Sanguinis
Verified
Journal Article
Closed access
PDF file
CMChristina Mikkelsen
Christina Mikkelsen
GMGaia Mori
Gaia Mori
SWSuzanna M. van Walraven
Suzanna M. van Walraven
JCJohanna Castrén
Johanna Castrén
SZSharon Zahra
Sharon Zahra
HUHenrik Ullum
Henrik Ullum